DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • South Korea
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
A065660 logo

Anterogen.Co.,Ltd. Stock Price

KOSDAQ:A065660 Community·₩153.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

A065660 Share Price Performance

₩15,300.00
-9550.00 (-38.43%)
​
₩15,300.00
-9550.00 (-38.43%)
​
Price ₩15,300.00
Fri, 11 Sep 26
Share Pricen/a

A065660 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with minimal risk.

1 Risk
1 Reward
View Full Analysis

Anterogen.Co.,Ltd. Key Details

₩8.4b

Revenue

₩5.5b

Cost of Revenue

₩2.9b

Gross Profit

₩4.5b

Other Expenses

-₩1.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-161.61
34.06%
-19.32%
0%
View Full Analysis

About A065660

Founded
2000
Employees
n/a
CEO
Seong-Gu Lee
WebsiteView website
anterogen.com

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as stem cell media program set, a cosmetic raw material. In addition, the company offers stem cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Recent A065660 News & Updates

Analysis Article • May 30

We're Not Very Worried About Anterogen.Co.Ltd's (KOSDAQ:065660) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

No updates

Anterogen.Co.,Ltd. Competitors

A207940 logo

Samsung BiologicsLtd

Symbol: KOSE:A207940
Market cap: ₩65.8t
A068270 logo

Celltrion

Symbol: KOSE:A068270
Market cap: ₩43.4t
A196170 logo

ALTEOGEN

Symbol: KOSDAQ:A196170
Market cap: ₩19.3t
A0126Z0 logo

Samsung Epis Holdings

Symbol: KOSE:A0126Z0
Market cap: ₩8.7t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide